Mercedes-Benz Financial Appoints Korean Unit’s CEO 
Leaked: New Huawei Luxeed SUV Images Fuel Anticipation for Tech Upgrades 
Peloton CEO Quits, Company Slashes 15% of Its Workforce as Restructuring Begins 
Tesla Drivers Get $4k Off 2024 Chevy Blazer EV; Costco Auto Slashes Prices on New EVs 
Starliner: Boeing prepares to launch its first crewed spacecraft as it chases after SpaceX 
Monster Beverage Sees Robust Growth with an 11.8% Revenue Surge 
China set to blast off to the far side of the Moon – here’s what it could discover 
Kellanova Beats Expectations with Strong Q1 Sales Amid Higher Prices 
Comcast Drops Bally Sports Channels, Stops Broadcast of MLB Team Games 
Sony Pictures, Apollo Looking to Jointly Acquire Paramount, Propose $26 Billion Cash Deal 
Arby’s Unveils New Menu Additions Plus Beyoncé-Inspired Chardonnay-Infused Sauce 
Ferrari Unveils New 12Cilindri Models, Bolstering Its Petrol-Powered Lineup 
Adidas Originals Teams up With Dingyun Zhang to Reinvent the Samba Silhouette 
Booking Holdings Surpasses Wall Street Expectations with Strong Q1 Earnings Amidst Global Travel Surge 
Tesla Granted South Korean Emission Credit Trading Rights by Environmental Ministry 
Boeing’s Starliner is about to launch − if successful, the test represents an important milestone for commercial spaceflight 
Taylor Swift, Justin Bieber, Billie Eilish Universal Music Label Signs New Deal With TikTok, Ending Dispute 
Roche is buying Genmark Diagnostics for $1.8 billion or €1.5 billion, and this was revealed on Monday, March 15. The price is for the full acquisition of the US-based molecular diagnostic tests maker.
The numbers in Roche’s newest investment
Roche’s price offer is equivalent to the price of $24.05 per share in an all-cash deal. This also showed a premium of 43% on GenMark’s closing stock on Feb. 10, just before the speculations about Roche’s plans to purchase GenMark made rounds, as per CNBC.
The Swiss pharmaceuticals manufacturer company decided to buy the leading provider of multiplex molecular diagnostic solutions so it can expand the business and make its presence in the diagnostics sector.
“Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases,” Thomas Schinecker, Roche’s chief executive officer, said via press release.
It was added that the acquisition that was approved by the respective board of directors of Roche and GenMark Diagnostics is expected to be completed within the second quarter of 2021. Once the negotiations are done, the latter’s main operations will not be moved but will continue in its current office location in Carlsbad, California.
The setup in the merger deal
The terms in the merger agreement were partly disclosed, and one clause states that Roche will immediately and directly initiate a tender offer to purchase all outstanding stocks of GenMark’s shares.
At any rate, GenMark’s portfolio will complement and further enhance Roche’s molecular diagnostics portfolio. It is also expected that the Swiss company will widen its global network reach when it starts to distribute GenMark’s items and products.
“As a part of Roche, we can accelerate our mission to enable rapid diagnosis of infectious disease to improve patient outcomes,” CEO of GenMark Diagnostics, Scott Mendel, said. “Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world.”
Finally, Mendel added that GenMark is thrilled to become part of the globally known Roche. He is confident that they made the right decision to move forward with the Swiss firm.
